CLINICAL CHEMISTRY ANALYZERS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)
Global clinical chemistry analyzers market is estimated to be valued at USD 13.82 billion in 2024 and is expected to reach USD 17.90 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 3.8% from 2024 to 2031. Clinical chemistry analyzers help in detecting various chemical imbalances in the blood and other body fluids to diagnose and monitor diseases. These provide critical information to physicians for effective diagnosis and treatment of various chronic and infectious conditions.
To learn more about this report, request sample copy
Global clinical chemistry analyzers market growth is driven by rising prevalence of chronic and lifestyle diseases globally. Furthermore, growing elderly population susceptible to various health issues can also boost sales. However, high cost of advanced analyzers may limit adoption in price sensitive developing regions. Increasing healthcare spending can offset this challenge in the future.
Increasing prevalence of chronic diseases
Rising number of individuals suffering from chronic diseases such as cancer, diabetes, cardiovascular diseases, and others can drive the clinical chemistry analyzers market growth globally. With changing lifestyle and dietary habits in developing countries and rising geriatric population worldwide, there has been rise in prevalence of chronic diseases that require regular monitoring and diagnosis.
Clinical chemistry analyzers play a crucial role in effectively managing and treating chronic diseases as these help in timely detection of even the subtle changes in the levels of important biomarkers, metabolites, electrolytes and other substances in blood, urine, stool or other body fluids of patients. This aids healthcare professionals in accurately diagnosing the disease, assessing disease progression, checking treatment effectiveness and making necessary modifications in treatment plans. Clinical chemistry analyzers are extensively used to closely monitor blood glucose and insulin levels in diabetes patients or to check liver and kidney function in cancer patients undergoing chemotheraphy.
Growing burden of chronic diseases exert tremendous pressure on overburdened healthcare systems globally. This has prompted governments and health agencies to focus on disease prevention through early detection as well as effective long term management of chronic conditions. This leads to increased adoption of clinical chemistry analyzers by hospitals, pathology labs and diagnostic centers to facilitate timely and accurate diagnosis as well as improved disease monitoring over the long term. Manufacturers are also developing sophisticated analyzers integrated with advanced technologies that can analyze multiple disease markers simultaneously and generate test results faster to better address the needs of patients with chronic illnesses.
For instance, in May 2023, according to WHO’s latest world health statistics report, growing threat of non-communicable diseases (NCDs) can account for 86% of deaths by 2050. The report also highlights the impact of COVID-19, which has stalled progress towards global health goals and reversed gains in areas like malaria and tuberculosis. Despite these challenges, global life expectancy has increased from 67 years in 2000 to 73 years in 2019, though the pandemic has deepened healthcare inequalities. The WHO calls for greater investment in health systems to achieve Sustainable Development Goals (SDGs).
Get actionable strategies to beat competition: Get instant access to report
Technological advancements
Global clinical chemistry analyzers market has witnessed significant technological advancements, which have enabled the development of novel and innovative product offerings. Automation, miniaturization, digitalization and artificial intelligence are some of the emerging technologies that are being integrated into new generation clinical chemistry analyzers.
The development of fully automated, random-access clinical chemistry analyzers that can perform a wide range of clinical chemistry, immunochemistry and specialized tests from small sample volumes with minimal human intervention, can boosting their adoption across healthcare facilities. Such high-throughput, random-access analyzers with improved workflow efficiency are ideal for busy clinical labs with high test volumes.
Miniaturization of analyzers combined with microfluidic and micro fabrication techniques have led to the development of compact, portable table-top analyzers suitable for point-of-care testing. This is especially beneficial in settings with space and resource constraints like doctor clinics, emergency rooms, nursing homes, and others. Digitalization enable connectivity of analyzers with laboratory information systems and hospital networks for secure, automated retrieval of test reports. AI backed clinical decision support functionalities in new generation analyzers are also improving diagnostic accuracy.
The paradigm shift towards miniaturized, automated, high-performance, intelligent and software-driven analyzers integrated with advanced technologies allows clinicians to gain valuable insights within minutes with just a small drop of sample. This boosts demand for upgraded clinical chemistry analyzers that can accelerate diagnostics and enable quicker clinical decisions. For instance, in May 2022, Mindray introduced the BS-600M, a robust and efficient chemistry analyzer that is designed to enhance productivity, efficiency, and reliability for medium-volume laboratories.
Key Takeaways from Analyst:
Global clinical chemistry analyzers market growth is driven by rising demand for advanced diagnostic solutions and increasing prevalence of chronic and lifestyle diseases worldwide. Growing geriatric population who are prone to various critical illnesses can also boost demand. Moreover, ongoing technological advancements in clinical chemistry analyzers focused on automation, miniaturization, and digitization can support their increased adoption in healthcare settings.
High costs of these advanced systems may limit wider access in price sensitive developing markets. Lack of skilled professionals required to operate complex analyzers can also pose a major challenge particularly in underdeveloped regions. Development of portable and home-use analyzers can help address accessibility issues and expand the market reach.
North America currently dominates the market due to well-established healthcare infrastructure and early availability of novel technologies. Asia Pacific is expected to emerge as the fastest growing regional market due to rising healthcare expenditure, growing patient base, and increasing investments by global players in emerging countries like China and India. Introduction of compact analyzers with enhanced functionalities will remain instrumental in boosting demand across major global markets in the near future.
Market Challenge - High initial investment costs
Global clinical chemistry analyzers market growth can be hampered due to high initial investment costs associated with setting up laboratories and purchasing advanced analyzers. Clinical chemistry analyzers equipped with latest technologies can cost anywhere between USD 50,000 to USD 300,000. Setting up the necessary laboratory infrastructure along with recurring costs of reagents, maintenance and skilled personnel further increases the overall expenditures. This high capital requirement poses a major restraint for small and medium hospitals as well as diagnostic centers in developing countries to automate their laboratories. The upfront investment decelerates the overall adoption rate of clinical chemistry analyzers devices. Moreover, budgetary constraints of public health systems also limit new procurement. To address this challenge, market players could offer flexible financing options and rental models to lower the entry barriers for customers.
Market Opportunity- Growth in point-of-care testing
Rising demand for point-of-care testing can offer lucrative opportunities for global clinical chemistry analyzers market players. Point-of-care testing employs portable devices that can be used near the patient in various settings to provide quick diagnostic results. It eliminates turnaround times for sending samples to central laboratories. Growing preference for self-monitoring and home-based testing can boost demand for point-of-care testing. Furthermore, increasing incidence of chronic and infectious diseases necessitates rapid testing solutions. Point-of-care analyzers suitable for resource-limited areas are gaining adoption in ambulatory surgical centers, physicians' offices, nursing homes and clinics. Market leaders are increasingly focusing on developing compact analyzers with upgraded features to capitalize on the expanding point-of-care testing domain.
Discover high revenue pocket segments and roadmap to it: Get instant access to report
Insights, By Product Type - Leading through innovation
In terms of product type, analyzers segment is estimated to contribute the highest market share of 41.2 % in 2024, owing to continuous technological advancements. Analyzers offer automated, accurate and high-throughput screening of various biomarkers, and this boosts their demand. Manufacturers are focusing on developing analyzers with advanced features such as connectivity, artificial intelligence, miniaturization and random access capabilities. This allows laboratories to streamline workflow and improve turnaround time for test results. Furthermore, automated analyzers reduce reliance on skilled technicians and ensure reliable, consistent outputs. The segment growth is driven by increasing application of lab automation and growing preference for point-of-care testing devices among healthcare providers.
Insights, By Types of Tests- Precision for Improved Patient Outcomes
In terms of types of tests, liver panels segment is estimated to contribute the highest market share of 42.3% in 2024. Liver function tests play a vital role in diagnosis, risk assessment and management of various diseases. Liver panels witness huge demand due to rising prevalence of lifestyle diseases linked to obesity, alcoholism and viral hepatitis. Clinical laboratories increasingly rely on liver panels to assist physicians in identifying liver abnormalities early and ensuring timely intervention. This benefits patients through better disease monitoring and improved therapeutic responses. Manufacturers are actively enhancing assay accuracy and standardizing result interpretation for liver panels. Their focus on research and validation studies also supports the clinical adoption of liver panel biomarkers for new disease indications.
Insights, By End User - Empowering Health Systems
In terms of end user, hospital segment is estimated to contribute the highest market share of 41.1% in 2024, due to growing in-house diagnostic capacities of hospitals. Laboratory testing forms an indispensable part of clinical workflows in hospitals. It aids clinicians in arriving at definitive diagnoses, assessing treatment responses, monitoring disease progression, performing pre-operative checks and facilitating discharge planning. Increased healthcare spending by governments worldwide on modernizing hospital infrastructure and expansion of clinical laboratories can boost demand for clinical chemistry analyzers in hospitals. Their large testing volumes also make hospitals an attractive target segment for instrument manufacturers. This ensures hospitals have access to advanced technologies at competitive rates.
To learn more about this report, request sample copy
North America dominates the global clinical chemistry analyzers market with an estimated market share of 40.3% in 2024. The U.S. accounts for the largest share due to presence of major players and mature healthcare infrastructure. Strong demand from acute care facilities, hospitals, and independent clinical laboratories in the region can drive the market growth. The region also has a well-developed distribution system and high consumer awareness regarding advanced healthcare diagnostics. Ongoing R&D activities to develop innovative testing solutions particularly focused on POC and immunoassay further drives the regional market. Favorable policies by government agencies such as USFDA for new product approvals and growing adoption of lab automation systems boosts demand for clinical chemistry analyzers in North America.
Asia Pacific is poised to be the fastest growing regional market during the forecast period. Rapidly developing economies in the region such as China and India present lucrative opportunities due to rising healthcare expenditures and increasing patient pool. Moreover, improving diagnostic infrastructure mainly across China and India expanding access to clinical testing can boost uptake of automated chemistry analyzers. Asia Pacific also has a thriving medical devices industry with presence of both international and domestic brands. Governments are collaborating with global market players and provide supports through favorable initiatives to enhance diagnostics capabilities locally, thus, driving APAC clinical chemistry analyzers market growth.
Clinical Chemistry Analyzers Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 13.82 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 3.8% | 2031 Value Projection: | US$ 17.90 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific Inc., Beckman Coulter (Danaher Corporation), Horiba Medical, Mindray Medical International Limited, Sysmex Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Ortho Clinical Diagnostics, PerkinElmer, Inc., Nihon Kohden Corporation, F. Hoffmann-La Roche AG, Boehringer Ingelheim, Diatron, Eppendorf AG, Luminex Corporation, A. Menarini Diagnostics, and Medtronic plc |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: Global Clinical Chemistry Analyzers Market consists of a wide range of medical devices that are used by hospitals and diagnostic laboratories to perform various blood and biochemical tests on patient samples. These clinical chemistry analyzers can perform tests like electrolyte, lipid, enzyme, renal function, blood gas, protein and immunoassay analysis to detect diseases and obtain other clinical information.
Share
About Author
Komal Dighe
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Credibility and Certifications
860519526
9001:2015
27001:2022
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowSelect a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
